Ken Griffin Sqz Biotechnologies CO Transaction History

Citadel Advisors LLC

  • $505 Billion
  • Q3 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022
SELL
$2.16 - $3.48 $100,116 - $161,298
-46,350 Reduced 73.29%
16,891 $38,000

Others Institutions Holding SQZ

# of Institutions
3
Shares Held
1.47M
Call Options Held
0
Put Options Held
0
View Full List

About SQZ Biotechnologies Co

SQZ Quotes by TradingView
  • Ticker SQZ
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,248,600
  • Market Cap $1.46M
  • Description
  • SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination ...
More about SQZ
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email